Genes and Race in Colon Cancer
Colon cancer is the second leading cause of cancer deaths in the United States and on track to be the leading cause of death in adults younger than 50 years by 2030.1 First-line therapy for metastatic colorectal cancer generally includes a fluoropyrimidine backbone with the addition of oxaliplatin, irinotecan, or both and a monoclonal antibody directed against the vascular endothelial growth factor receptor or the epidermal growth factor receptor (EGFR).2 The Cancer and Leukemia Group B (CALGB)/Southwest Oncology Group (SWOG) 80405 trial investigated first-line palliative infusional fluorouracil, leucovorin, and oxaliplatin or fluorouracil, leucovorin, and irinotecan with either bevacizumab or cetuximab and serves as a seminal study supporting this approach. Key findings of CALGB/SWOG 80405 were that there was no difference in overall survival (OS) between the regimens in KRAS wild-type tumors.3 In addition, tumors arising from the left colon had better outcomes than those arising from the right, with a median OS of 36.0 versus 16.7 months (hazard ratio, 1.87 [95% CI, 1.48 to 2.32]; P < .0001)...
History
Refereed
- No
Volume
42Issue number
4Page range
369-372Publication title
Journal of Clinical OncologyISSN
0732-183XExternal DOI
Publisher
American Society of Clinical Oncology (ASCO)Location
United StatesFile version
- Published version
Language
- eng
Item sub-type
EditorialMedia of output
Print-ElectronicOfficial URL
Affiliated with
- School of Life Sciences Outputs